Abstract:Secondary mutations of FLT3 have become the main mechanism of FLT3 inhibitor resistance that presents a significant clinical challenge. Herein, a series of pyrazole-3-amine derivatives were synthesized and optimized to overcome the common secondary resistance mutations of FLT3. The structure–activity relationship and molecular dynamics simulation studies illustrated that the ribose region of FLT3 could be occupied to help address the obstacle of secondary mutations. Among those derivatives, compound 67 exhibited potent and selective inhibitory activities against FLT3-ITD-positive acute myeloid leukemia (AML) cells and possessed equivalent potency against transformed BaF3 cells with a variety of secondary mutations. Besides, cellular mechanism assays demonstrated that 67 strongly inhibited phosphorylation of FLT3 and its downstream signaling factors, as well as induced cell cycle arrest and apoptosis in MV4-11 cells. In the MV4-11 xenograft models, 67 exhibited potent antitumor potency without obvious toxicity. Taken together, these results demonstrated that 67 might be a drug candidate for the treatment of FLT3-ITD-positive AML.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01196.Molecular formula strings (CSV)FLT3 homology (PDB)Molecular modeling information involved in compound Lu-46 with FLT3-WT (PDB)Molecular modeling information involved in compound Lu-46 with FLT3-F691L (PDB)Molecular modeling information involved in compound 31 with FLT3-WT (PDB)Molecular modeling information involved in compound 31 with FLT3-F691L (PDB)Molecular modeling information involved in compound 41 with FLT3-WT (PDB)Molecular modeling information involved in compound 55 with FLT3-WT (PDB)Molecular modeling information involved in compound 55 with FLT3-F691L (PDB)Molecular modeling information involved in compound 67 with FLT3-WT (PDB)Molecular modeling information involved in compound 67 with FLT3-F691L (PDB)Molecular modeling information involved in compound 67 with FLT3-D835V (PDB)Molecular modeling information involved in compound 67 with FLT3-Y842H (PDB)Molecular modeling information involved in compound 67 with FLT3-N676D (PDB)Figures for the manuscript (ZIP)Average root-mean-square deviation (rmsd) of backbone atoms of various FLT3 protein models and compound 55 throughout MD simulations; halogen bond analysis of 55 bound to FLT3-WT and FLT3-F691L models during MD simulations (40–50 ns); cell viability of HCD57, HCD57-FLT3-ITD, and HCD57-FLT3-D835Y cells after treating with compound 67; average rmsd of backbone atoms of various FLT3 protein models and compound 67 throughout the MD simulations; halogen bond analysis of 67 bound to various FLT3 models during MD simulations (90–100 ns); apoptosis induction and cell cycle arrest effects of compound 67 on HCD57, HCD-FLT3-ITD, and HCD-FLT3-D835Y cells at 100 nM concentration; peripheral blood counts of MV4-11 xenograft tumor mice treated with compound 67; and 1H NMR and 13C NMR spectra for target compound molecular formula strings (PDF)This article has not yet been cited by other publications.

Gaining Selectivity in the Back Pocket of Fms-Like Tyrosine Kinase 3: A Case Study

Design and Synthesis of Selective FLT3 Inhibitors Via Exploration of Back Pocket II

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1

Recent advances in FLT3 inhibitors for acute myeloid leukemia.

Identification of 2-Aminopyrimidine Derivatives As FLT3 Kinase Inhibitors with High Selectivity over C-Kit.

Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor

Discovery of a Potent and Selective FLT3 Inhibitor ( Z )- N -(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1 H -pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia

Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia.

Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study

Discovery and structure − activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors

Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia

Discover Novel Covalent Inhibitors Targeting FLT3 Through Hybrid Virtual Screening Strategy.

Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia

Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach

Design, synthesis, and evaluation of pyrido.[3,4–b]pyrazin-2(1 H )-one derivatives as potent FLT3 inhibitors

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib.